The genomics market in China is expected to reach a projected revenue of US$ 6,070.8 million by 2033. A compound annual growth rate of 19.9% is expected of China genomics market from 2026 to 2033.
Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A
Other key industry trends
In terms of revenue, China accounted for 7.5% of the genomics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China genomics market is projected to lead the regional market in terms of revenue in 2033.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,809.7 million by 2033.
The growing biotechnological and pharmaceutical sector has a direct positive impact on the growth of the genomics market. In addition, with the development of these industries, there is increased biotechnological development in China, which has led to an increase in the market share of genomics in China.
Improving healthcare infrastructure and growing healthcare expenditure by pharmaceutical companies and the government is expected to drive the genomics market. For instance, the Chinese government launched an initiative of Precision Medicine that could amount to around USD 9 billion over the next 15 years.
China has one of the fastest-growing and most advanced genomics markets. In 2020, the country’s genetic testing companies raised approximately USD 3 billion in financing. NGS can improve human health by enabling early diagnosis of rare diseases, more pathogen monitoring, and improved outcomes for cancer patients.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Genomics Market Outlook will help companies and investors design strategic landscapes.
Functional Genomics was the largest segment with a revenue share of 34.48% in 2025.
Horizon Databook has segmented the China genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2021 to 2033.
The growing biotechnological and pharmaceutical sector has a direct positive impact on the growth of the genomics market. In addition, with the development of these industries, there is increased biotechnological development in China, which has led to an increase in the market share of genomics in China.
Improving healthcare infrastructure and growing healthcare expenditure by pharmaceutical companies and the government is expected to drive the genomics market. For instance, the Chinese government launched an initiative of Precision Medicine that could amount to around USD 9 billion over the next 15 years.
China has one of the fastest-growing and most advanced genomics markets. In 2020, the country’s genetic testing companies raised approximately USD 3 billion in financing. NGS can improve human health by enabling early diagnosis of rare diseases, more pathogen monitoring, and improved outcomes for cancer patients.
China Genomics Market Application Outlook (Revenue, USD Million , 2021-2033)
Functional Genomics
Epigenomics
Pathway Analysis
Biomarker Discovery
Others
China Genomics Market Deliverable Outlook (Revenue, USD Million , 2021-2033)
Products
Services
China Genomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics
Academic and Government Institutes
Clinical Research
Other End Users
Reasons to subscribe to Genomics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Genomics Market Outlook databook
Our clientele includes a mix of Genomics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Genomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Genomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.